CEACAM6 and neoplasm: All these results suggested that 131I radiolabeling preserved specificity, affinity and immunoreactivity of tinurilimab, and 131I‐tinurilimab may be applicable for the therapy of CEACAM6‐positve tumor (LUAD) or malignant pulmonary nodules.